Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab with Pomalidomide and Dexamethasone in RRMM
NCT05298683Phase 2Not yet recruiting
- Sponsor
- Hellenic Society of Hematology
- Start
- May 2022
- Primary completion
- Nov 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Planned start May 2022; status: not yet recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05298683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298683.